Microbial Testing Is Not Enough: 5 FDA Risks Cosmetics Exporters Must Check [GeXPs26-0626EN]

Microbial Testing Is Not Enough: 5 FDA Risks Cosmetics Exporters Must Check

FDA Import Alert 53-17 has highlighted the serious consequences of microbiological contamination in cosmetic products. However, passing a final-product microbial test does not by itself ensure that a cosmetic is ready for the U.S. market.

Imported cosmetics may be examined at the time of entry. Products that appear to be adulterated or misbranded may be detained, required to be brought into compliance, re-exported, destroyed, or refused entry.

For global beauty brands, contract manufacturers, and OEM/ODM companies, U.S. market readiness requires more than a laboratory report. Regulatory and quality teams should review the following five connected risk areas before shipping cosmetic products to the United States.

1. Microbial Control Beyond Final-Product Testing

Relying only on a negative microbial result from a finished batch may leave important risks unaddressed. Contamination can arise from raw materials, manufacturing water, equipment, filling operations, packaging, storage, or transportation.

Companies should maintain controls and records showing how microbial risks are managed throughout manufacturing and distribution. This may include water-system controls, sanitation procedures, environmental monitoring, preservative-effectiveness data, batch records, and investigations of deviations or out-of-specification results.

The key question is not only whether one tested batch passed, but whether the company can demonstrate that the product is manufactured, packed, and stored under conditions that prevent harmful contamination.

2. Color Additive Violations

Color additives are regulated differently from most other cosmetic ingredients in the United States. A color additive that may be lawfully used in Europe, South Korea, Vietnam, or another market is not automatically permitted for the same cosmetic use in the United States.

Exporters should confirm:

• whether the color additive is permitted for use in cosmetics in the United States;
• whether it is permitted for the intended area of use, such as the eye area, lips, or externally applied cosmetics;
• whether FDA batch certification is required;
• whether the color additive is correctly declared in the ingredient list; and
• whether the supplier can provide appropriate identity, purity, and certification documentation.

A non-permitted, improperly used, uncertified, or undeclared color additive may cause a cosmetic to be considered adulterated or misbranded and may result in regulatory or import action.

3. Labeling Errors and Misbranding

A cosmetic with an acceptable formulation may still face import or market-access problems if its labeling does not comply with U.S. requirements.

Common areas requiring review include:

• the identity of the product;
• the net quantity of contents;
• the ingredient declaration;
• the name and place of business of the manufacturer, packer, or distributor;
• required warnings and caution statements;
• English-language information required for the U.S. market; and
• contact information through which the responsible person can receive adverse-event reports.

Country-of-origin marking and customs documentation should also be reviewed separately under applicable U.S. customs requirements.

Do not assume that an ingredient list prepared for another market can be used without modification. Ingredient names, placement, prominence, formatting, and required statements should be checked against U.S. labeling rules.

4. Drug-Like or Therapeutic Claims

In the United States, product classification depends largely on intended use. Intended use may be established through packaging, websites, online sales pages, advertising, social media, consumer directions, and other promotional materials.

Claims that a product treats acne, reduces inflammation, heals wounds, restores hair growth, relieves pain, prevents disease, or affects the structure or function of the body may cause the product to be regulated as a drug, or as both a cosmetic and a drug.

Such products must comply with the applicable drug requirements. A product marketed with drug claims without meeting those requirements may be subject to warning letters, detention, refusal of admission, or other enforcement action.

Exporters should therefore review not only the physical label, but also all digital and distributor-controlled marketing content.

5. MoCRA Registration, Listing, and Safety Records

The Modernization of Cosmetics Regulation Act of 2022, or MoCRA, introduced significant new obligations for the cosmetics industry.

Unless an exemption applies, relevant companies should verify that:

• applicable manufacturing or processing facilities are registered with FDA;
• facility registrations are renewed as required;
• marketed cosmetic products are properly listed;
• product listings are updated when required;
• adequate safety substantiation records are maintained;
• serious adverse events can be received, evaluated, documented, and reported within the required timeframe; and
• traceability and recall-response records are available.

MoCRA compliance should not be treated as a one-time filing exercise. Product listings, safety documentation, labels, formulations, facilities, and adverse-event procedures should be reviewed whenever relevant information changes.

Key Summary: A passing microbial test is only one part of U.S. market readiness. Cosmetics exporters should align microbial controls, color additives, labeling, marketing claims, and MoCRA records before shipment.

Pre-Export Cosmetics Compliance Checklist

• Microbial Controls: Can the company demonstrate control of water, raw materials, equipment, filling, packaging, storage, and transportation?
• Colors and Formulation: Are all color additives permitted for the intended use, and is any required FDA batch certification available?
• Labeling: Does the U.S. label contain the required identity, net quantity, ingredient, business, warning, and adverse-event contact information?
• Claims Review: Have packaging, websites, online marketplaces, distributor materials, and social media been reviewed for drug-like claims?
• MoCRA Status: Where applicable, are facility registrations and product listings current, and are safety and adverse-event records maintained?

Three Recommended Actions for Export Managers

1. Conduct a Cross-Functional Compliance Review: Bring regulatory, quality, R&D, manufacturing, marketing, and export teams together. The formulation, label, claims, records, and shipping documents should tell the same compliance story.
```
2. Verify Supplier Documentation: Obtain ingredient specifications, certificates of analysis, color-additive documentation, batch-certification information where required, and records supporting traceability.
3. Maintain a Current MoCRA Compliance File: Assign clear responsibility for reviewing facility information, product listings, safety substantiation, serious adverse-event procedures, and material changes to products or labels.
```

Final Takeaway

U.S. cosmetics compliance is not established by a single test certificate.

Before shipment, exporters should confirm that the product, manufacturing controls, color additives, U.S. label, marketing claims, safety records, and applicable MoCRA submissions are aligned.

The most important question is not simply, “Did the product pass the test?”

It is:

Can the company demonstrate that the product is safe, correctly labeled, appropriately marketed, and supported by current regulatory records?